Regional molecular genetics centers in thoracic oncology: what and who should be tested? - Archive ouverte HAL Access content directly
Journal Articles Bulletin du Cancer Year : 2013

Regional molecular genetics centers in thoracic oncology: what and who should be tested?

(1, 2) , (1, 2) , (3) , (4) , (1, 2) , (3) , (4) , (2, 3)
1
2
3
4

Abstract

Management of NSCLC patients is more and more individualized especially on the base of bioguided treatments. In order to guarantee an access for all the patients too this type of strategy, the French NCI supports since 2006 a nationwide network of 28 regional genetics center. The financial support is based on public funds. The French NCI recommends today the assessment of seven biomarkers for all stage IV non squamous NSCLC patients. Due to financial and technical reasons, this recommendation must be followed. However, the molecular profiling of lung cancer patients would ideally be extended across all stages and all histological types of the disease in order to improve our knowledge in this field and provides the patient with an opportunity to access a bioguided treatment as frequently as possible.
Not file

Dates and versions

hal-01708071 , version 1 (13-02-2018)

Identifiers

  • HAL Id : hal-01708071 , version 1

Cite

Fabrice Barlési, Pascale Tomasini, Frédéric Fina, Véronique Secq, Laurent Greillier, et al.. Regional molecular genetics centers in thoracic oncology: what and who should be tested?. Bulletin du Cancer, 2013, 100 (7-8), pp.737-741. ⟨hal-01708071⟩
25 View
0 Download

Share

Gmail Facebook Twitter LinkedIn More